Congressional Medicare Advisers Say 340B Has Minor Effect on Cancer Drug Spending and Patient Cost-Sharing

In Federal, Research/ReportsMarch 13, 202058 Views

Do 340B drug discounts induce hospitals to furnish more-expensive drugs to treat cancer than they otherwise would, raising patients’ coinsurance obligations and the cost of cancer care overall?

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Congressional Medicare Advisers Say 340B Has Minor Effect on Cancer Drug Spending and Patient Cost-Sharing

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Congressional Medicare Advisers Say 340B Has Minor Effect on Cancer Drug Spending and Patient Cost-Sharing

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Site Footer